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By Stephen Bradt
For the first time, researchers have success-
fully used gene therapy to treat a disease that
affects organs throughout the body of a large
animal.
The study, led by Dr. Mark E. Haskins,
V’69, of the School and Dr. Katherine Parker
Ponder of the Washington University School
of Medicine in St.
Louis, involved dogs
with a rare disorder
in which an enzyme
deficiency causes
clouding of the
corneas, cardiac dis-
ease and bone abnor-
malities leading to
loss of mobility by
six months of age.
Newborn dogs treat-
ed with hepatic gene
therapy maintained
near-normal mobili-
ty throughout the
17-month study and
showed little evi-
dence of the other
debilitating signs
normally associated
with the disease.
“While gene ther-
apy has been used
previously in dogs,
this is the first use to
treat a disorder
affecting multiple organ systems throughout
the body,” said Haskins, professor of pathology
and medical genetics at the School. “Previous
applications of gene therapy in dogs have tar-
geted disorders affecting a single bodily func-
tion, such as vision or blood clotting. Like
many diseases that we might eventually like to
treat with gene therapy, this one has complex,
multisystemic effects.”
The experiments involved seven dogs with
mucopolysaccharidosis VII, a disorder in
which the enzyme β-glucuronidase is deficient
in activity. Also known as Sly syndrome, MPS
VII is among a constellation of lysosomal stor-
age diseases; in humans, such disorders
include Tay Sachs disease and Gaucher disease.
“In theory, the approach should be applica-
ble to other lysosomal storage diseases, with
the exception of those that affect the central
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nervous system,” said Ponder, associate profes-
sor of medicine and assistant professor of bio-
chemistry and biophysics at Washington Uni-
versity. “We’re hopeful that the approach might
also be applicable to hemophilia.”
Lysosomal storage diseases such as MPS VII
can be treated through enzyme replacement
therapy, but that approach requires regular
intravenous injections and is prohibitively
expensive. Bone-marrow transplantation is
another option but is risky, and compatible
donors are often unavailable.
MPS diseases affect 1 in 27,000 live births
among humans, but the disease is debilitating
for patients and emotionally wrenching for
their families. Human symptoms include
growth retardation, mobility problems, facial
deformities, corneal clouding, liver and heart
valve abnormalities and mental retardation,
among others. Most patients die in childhood.
“The gene therapy research of Drs. Haskins,
Ponder and collaborators involving MPS VII
dogs has significant implications for all MPS
disorders,” said Barbara Wedehase, executive
director of the National MPS Society, an organ-
ization of parents of children with MPS. “Their
current and ongoing research will provide new
insights into the treatment of individuals
affected with these devastating disorders.”
In these experiments, two- to three-day-old
dogs with MPS VII received four injections of a
retroviral vector expressing canine β-glucuroni-
dase. The vector used was made from the
Moloney murine leukemia virus with a liver-
specific promoter; at several days of age, canine
liver growth is so
rapid that trans-
duction occurs
readily and β-glu-
curonidase is
secreted continu-
ously into the
bloodstream.
The enzyme’s
activity was subse-
quently found at
normal, stable
levels for up to 14
months in the
treated dogs; one
dog has produced
60 times normal
enzyme for 17
months. Unlike
other dogs with
MPS VII, the treat-
ed dogs gained
weight normally,
attaining nearly 90
percent the weight
of their unaffected
littermates, and
avoided the serious side effects normally associ-
ated with lysosomal storage diseases. The β-
glucuronidase gene does not appear to have
been inserted into the germ line.
Haskins and Ponder were joined in the
research by Drs. John R. Melniczek, V’92,
Margaret A. Weil, Thomas M. O’Malley,
Patricia A. O’Donnell, Van W. Knox, Hamutal
Mazrier, N. Matthew Ellinwood, Meg Sleeper,
V’93, Susan W. Volk, V’95, Jean Zweigle and
John H. Wolfe, V’82 of Penn’s School of
Veterinary Medicine; Albert M. Maguire of
Penn’s School of Medicine; Lingfei Xu and
Robert L. Mango of Washington University’s
School of Medicine; and Gustavo D. Aguirre,
V’68 of Cornell University’s College of
Veterinary Medicine. The work was funded by
the National Institutes of Health.
Dogs with the genetic disease mucopolysaccharidosis VII and a diagram of the retroviral vector used in intravenous
neonatal gene therapy. The untreated 5 month-old dog on the right is unable to stand. The 17 month-old dog on the
left, treated at 3 days of age, can stand and run and has not developed most signs of the disease.
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